"Evidence based" evaluation of treatment in ADHD. Attention deficit hyperactivity disorder (ADHD) is marked by limitations in diagnostic accuracy, psychobiological characterisation and assessment of treatment efficacy. A national consortium of scientists and clinicians is planning to address these issues using an assessment protocol recently developed by the Brain Resource Company Ltd, which involves integrated neuroscientific and psychometric measurement that taps many of the brain's informati ...."Evidence based" evaluation of treatment in ADHD. Attention deficit hyperactivity disorder (ADHD) is marked by limitations in diagnostic accuracy, psychobiological characterisation and assessment of treatment efficacy. A national consortium of scientists and clinicians is planning to address these issues using an assessment protocol recently developed by the Brain Resource Company Ltd, which involves integrated neuroscientific and psychometric measurement that taps many of the brain's information processing networks. Specifically, the aims of the project are to identify biological and cognitive markers that reflect ADHD in its untreated form, and markers that discriminate treatment effects relative to the pre treatment profile. The results from this study will be translated into a product that uses the protocol to provide a service able to profile ADHD more accurately and evaluate the effects of treatment.Read moreRead less
Development of a diagnostic microarray to detect aneuploidy in single cells. Chromosomal abnormalities account for about 10 per cent of all babies born with a defect. The risk of chromosomal abnormalities increases with maternal age and in patients with fertility problems. It has been estimated that 50 per cent of all embryos are aneuploid. Chromosomal aberrations also occur in the vast majority of tumours in humans. Accurate and rapid detection of chromosomal defects is an important health ser ....Development of a diagnostic microarray to detect aneuploidy in single cells. Chromosomal abnormalities account for about 10 per cent of all babies born with a defect. The risk of chromosomal abnormalities increases with maternal age and in patients with fertility problems. It has been estimated that 50 per cent of all embryos are aneuploid. Chromosomal aberrations also occur in the vast majority of tumours in humans. Accurate and rapid detection of chromosomal defects is an important health service delivered to the Australian public. This project aims to develop better tests for application in prenatal diagnostics including non-invasive testing of fetal cells from maternal circulation or cervical samples at 6-13 weeks gestation, IVF and cancer diagnostics.Read moreRead less